The complex price setting and reimbursement of non-industrial advanced therapy medicinal products
Open Access
- 9 March 2026
- journal article
- research article
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1)
Abstract
Advanced Therapy Medicinal Products (ATMPs) developed under the Hospital Exemption (HE) offer innovative treatments for patients with unmet medical needs,Keywords
This publication has 23 references indexed in Scilit:
- A Framework for Considering the Role of the Public Sector in R&D of Health TechnologyPharmaceutical Medicine, 2025
- Academic challenges on advanced therapy medicinal products’ development: a regulatory perspectiveCytotherapy, 2024
- Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost DatabaseThe European Journal of Health Economics, 2022
- Value-based pricing for advanced therapy medicinal products: emerging affordability solutionsThe European Journal of Health Economics, 2021
- An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impactCytotherapy, 2020
- What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costingsCytotherapy, 2020
- Pharmaceutical drug development: high drug prices and the hidden role of public fundingBiologia Futura, 2020
- Cost of decentralized CAR T‐cell production in an academic nonprofit settingInternational Journal of Cancer, 2020
- A general framework for classifying costing methods for economic evaluation of health careThe European Journal of Health Economics, 2020
- Emergent Challenges in Determining Costs for Economic EvaluationsPharmacoEconomics, 2016